Study Progression on Non-small Cell Lung Cancer with EGFR Mutation 
Treated by Immune Checkpoint Inhibitors

In recent years, epidermal growth factor receptor tyrosine kinase inhibitors have been recommended by many guidelines as first-line drugs for advanced non-small cell lung cancer (NSCLC) with EGFR gene mutations and no resistance. However, with the prolongation of medication time, most appear acquire...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Rilan BAI, Naifei CHEN, Jiuwei CUI
التنسيق: Artigo
اللغة:Chinês
منشور في: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2018-08-01
سلاسل:Chinese Journal of Lung Cancer
الموضوعات:
Immune checkpoint inhibitors
Lung neoplasms
EGFR mutation
PD-L1
الوصول للمادة أونلاين:http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.11
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة